Indica Labs, the leading provider of AI-powered digital pathology solutions, announces today the expansion of their macrodissection suite with the launch of CRC Macrodissect AI.
Indica Labs Expands their Macrodissection Suite with the Launch of CRC Macrodissect AI Read More »
15 May 2025 | Indica Labs is pleased to announce our Boston HALO® User Group Meeting at Le Méridien Boston Cambridge on May 15 from 9:30 am – 4 pm.
Indica Labs’ Boston HALO® User Group Meeting Read More »
In digital pathology, advancements and proliferation in artificial intelligence (AI) and digital laboratory equipment are enabling streamlined workflows and new insights. However, they can also multiply the potential challenges laboratories face with software integration.
Open Pathology and AI Integrations: Empowering Labs with Choice Read More »
27 March 2025 | Learn about the latest advancements in AI-powered pathology. In this webinar, we’ll introduce CRC Macrodissect AI, an advanced solution designed to assist in colorectal cancer tumor content scoring and selecting regions for downstream macrodissection.
CRC Macrodissect AI and Breast HER2 AI Sneak Peek Read More »
Albuquerque, NM and Grapevine, TX, February 4, 2025 – Indica Labs, the global leader of AI-powered digital pathology and Versant Diagnostics, an independent physician services company and proponent of next-generation digital pathology, announce today that Versant Diagnostics has chosen the HALO AP® platform from Indica Labs to further support their mission of helping world leading pathologists transition from conventional pathology to cutting edge digital technology.
Vista, CA, and Albuquerque, NM, January 8, 2025 – Leica Biosystems, a global leader in anatomic and digital pathology solutions, and Indica Labs, a global leader in artificial intelligence (AI)-powered digital pathology software, today announced that Leica Biosystems has agreed to make a significant strategic investment in Indica Labs. This partnership has the potential to accelerate AI-enabled companion diagnostics (CDx) and support discoveries and treatments based on discrete or complex biomarker expression profiles which are not discernable by the human eye.
Albuquerque, NM, 19 December 2024 -Indica Labs announced today that Molecular Pathology Laboratory Network, Inc. (MPLN), a leader in laboratory medicine, hematopathology, and solid tumor oncology testing, has selected the HALO AP® platform from Indica Labs to deliver digital pathology services to both clinical reference labs and biopharma clients.
13 February 2025 | Join us for a 1-hour webinar where we introduce our Cloud Services offering and hear directly from a customer at the University of Washington who achieved a 40% cost reduction in their HALO® deployment on AWS in four months by switching to Cloud Services.
Deploying HALO® in the Cloud at the University of Washington BRaIN Lab Read More »
As 2024 draws to a close, we at Indica Labs would like to thank the customers and collaborators who helped fill 2024 with exciting discoveries, events, and partnerships. It is a great honor to have played a part in customers’ contributions to scientific fields ranging from immuno-oncology to infectious disease, immunology, neuroscience, and metabolism.
Looking Back: Reviewing 2024 at Indica Labs Read More »
Albuquerque, NM, 11 December 2024 -Indica Labs, the global leader in AI-powered digital pathology, today announces that the Institute of Tissue Medicine and Pathology at the University of Bern, a leading university based pathology institute in Switzerland, has selected HALO AP® for the Institute’s first-in-country digital pathology deployment in the cloud powered by Amazon Web Services, Inc. (AWS).
